TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 54273

Group type: EXPERIMENTAL
Intervention: Hepatitis B immune globulin (3 cc administered intramuscularly within seven days after admission, repeated three months later)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Conventional gammaglobulin (3 cc administered intramuscularly within seven days after admission, repeated three months later)
Number of subjects: 0
Study: 31782309

Group type: EXPERIMENTAL
Intervention: Electroacupuncture stimulation for 10 minutes
Number of subjects: 15

Group type: COMPARATOR
Intervention: Control (no EA stimulation)
Number of subjects: 15
Study: 31603295

Group type: EXPERIMENTAL
Intervention: Supera + DCB
Number of subjects: 160

Group type: COMPARATOR
Intervention: Supera
Number of subjects: 160

Group type: COMPARATOR
Intervention: Both groups
Number of subjects: 160
Study: 28835403

Group type: EXPERIMENTAL
Intervention: Alemtuzumab
Number of subjects: 0
Study: 26115111

Group type: EXPERIMENTAL
Intervention: Test condition (n = 43) - learners wrote a short test consisting of 10 short-answer questions (SAQs)
Number of subjects: 83

Group type: COMPARATOR
Intervention: Study condition (n = 40) - learners studied the same information
Number of subjects: 83
Study: 23624448

Group type: EXPERIMENTAL
Intervention: Oxygen supplementation
Number of subjects: 70

Group type: COMPARATOR
Intervention: Room air breathing
Number of subjects: 70
Study: 22224253

Group type: EXPERIMENTAL
Intervention: Rhubarb (10 g by nasal feeding, 5 g L-glutamine by oral administration, three times per day)
Number of subjects: 30
Study: 19615944

Group type: EXPERIMENTAL
Intervention: G‐CSF and AMD3100
Number of subjects: 0

Group type: COMPARATOR
Intervention: G‐CSF
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: AMD3100
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: AMD3100 mobilized grafts
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Chemokine axis‐mobilized PBSC
Number of subjects: 0
Study: 17091142

Group type: EXPERIMENTAL
Intervention: Thin major connector analogs (MCAs)
Number of subjects: 19

Group type: EXPERIMENTAL
Intervention: Wide major connector analogs (MCAs)
Number of subjects: 19

Group type: COMPARATOR
Intervention: Thick major connector analogs (MCAs)
Number of subjects: 19

Group type: COMPARATOR
Intervention: Narrow major connector analogs (MCAs)
Number of subjects: 19
Study: 14872175

Group type: EXPERIMENTAL
Intervention: Cerebrospinal fluid (CSF) concentrations of MCP-1
Number of subjects: 23

Group type: EXPERIMENTAL
Intervention: Cerebrospinal fluid (CSF) concentrations of tumor necrosis factor-alpha
Number of subjects: 23

Group type: EXPERIMENTAL
Intervention: Cerebrospinal fluid (CSF) concentrations of RANTES
Number of subjects: 23

Group type: EXPERIMENTAL
Intervention: Cerebrospinal fluid (CSF) concentrations of MMP-9
Number of subjects: 23

Group type: EXPERIMENTAL
Intervention: Cerebrospinal fluid (CSF) concentrations of MIP-1-alpha and MIP-1-beta
Number of subjects: 23

Group type: EXPERIMENTAL
Intervention: Change in CSF concentrations of MCP-1 and MMP-9 from baseline to Week 48
Number of subjects: 23
Study: 11320383

Group type: EXPERIMENTAL
Intervention: Amiodarone (1200 mg loading dose 1 day before surgery, followed by 200 mg daily for 7 days)
Number of subjects: 315

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 315

Group type: EXPERIMENTAL
Intervention: Amiodarone (in elderly patients age >= 60 years)
Number of subjects: 315

Group type: COMPARATOR
Intervention: Placebo (in elderly patients age >= 60 years)
Number of subjects: 315
Study: 9223880

Group type: EXPERIMENTAL
Intervention: Group F (fast; injection speed >= 0.2 ml.s‐1)
Number of subjects: 42

Group type: EXPERIMENTAL
Intervention: Group M (moderate; 0.1 < injection speed < 0.2 ml.s‐1)
Number of subjects: 42

Group type: EXPERIMENTAL
Intervention: Group S (slow; injection speed <= 0.1 ml.s‐1)
Number of subjects: 42
Study: 8094648

Group type: EXPERIMENTAL
Intervention: Pirenzepine 200 mg
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Pyridostigmine 120 mg
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: GH pretreatment
Number of subjects: 20

Group type: COMPARATOR
Intervention: GHRH alone
Number of subjects: 20
Study: 3673526

Group type: EXPERIMENTAL
Intervention: Cefuroxime 0.75 grams intravenously thrice daily for 24 hours (Group B)
Number of subjects: 121

Group type: COMPARATOR
Intervention: Cefuroxime for 24 hours plus 6 days of oral cephalexin (Group A)
Number of subjects: 121
Study: 30520217

Group type: EXPERIMENTAL
Intervention: Insulin glargine 100 U/mL (Gla-100)
Number of subjects: 3415
Study: 29024214

Group type: EXPERIMENTAL
Intervention: Intracerebral insertion of stem cells
Number of subjects: 66

Group type: COMPARATOR
Intervention: Placebo neurosurgery
Number of subjects: 66

Group type: EXPERIMENTAL
Intervention: Both interventions
Number of subjects: 66
Study: 26739996

Group type: EXPERIMENTAL
Intervention: Mediterranean diet (MedDiet) intervention (high in MUFA)
Number of subjects: 7098

Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 7098

Group type: EXPERIMENTAL
Intervention: T2D subjects with CLOCK-rs4580704 SNP
Number of subjects: 7098
Study: 24070573

Group type: EXPERIMENTAL
Intervention: Texture 1 (Algeos)
Number of subjects: 46

Group type: EXPERIMENTAL
Intervention: Texture 2 (Crocs™)
Number of subjects: 46

Group type: COMPARATOR
Intervention: Control (smooth insoles)
Number of subjects: 46
Study: 22434665

Group type: EXPERIMENTAL
Intervention: Paclitaxel-carboplatin regimen
Number of subjects: 528

Group type: COMPARATOR
Intervention: Gemcitabine-cisplatin regimen
Number of subjects: 528

Group type: EXPERIMENTAL
Intervention: RASSF1A methylation
Number of subjects: 528

Group type: EXPERIMENTAL
Intervention: Prognostic model including RASSF1A, DAPK1, and tumor stage
Number of subjects: 528
Study: 19397645

Group type: EXPERIMENTAL
Intervention: 500 U of botulinum toxin type A (BT‐A) reconstituted 15 days before injection
Number of subjects: 105

Group type: EXPERIMENTAL
Intervention: 500 U of botulinum toxin type A (BT‐A) reconstituted 8 days before injection
Number of subjects: 105

Group type: EXPERIMENTAL
Intervention: 500 U of botulinum toxin type A (BT‐A) reconstituted 8 hours before injection
Number of subjects: 105

Group type: COMPARATOR
Intervention: Control group (not explicitly defined)
Number of subjects: 105
Study: 17615252

Group type: EXPERIMENTAL
Intervention: 10 mg/kg mesna
Number of subjects: 11

Group type: COMPARATOR
Intervention: Vehicle
Number of subjects: 11
Study: 16167153

Group type: EXPERIMENTAL
Intervention: Sealant placed after tooth separation on all enamel lesions (n=17)
Number of subjects: 50

Group type: EXPERIMENTAL
Intervention: Sealant and fluoride varnish in a split-mouth design (n=7)
Number of subjects: 50

Group type: COMPARATOR
Intervention: Fluoride varnish treatment without tooth separation (Control group, n=26)
Number of subjects: 50

Group type: EXPERIMENTAL
Intervention: Fluoride varnish treatment (split-mouth design)
Number of subjects: 50

Group type: EXPERIMENTAL
Intervention: Sealant groups
Number of subjects: 50

Group type: COMPARATOR
Intervention: Fluoride varnish groups
Number of subjects: 50
Study: 12119245

Group type: EXPERIMENTAL
Intervention: Sustained ventricular arrhythmias (VF and VT)
Number of subjects: 26416
Study: 9786261

Group type: EXPERIMENTAL
Intervention: Color Duplex Ultrasound (CDU)
Number of subjects: 79

Group type: COMPARATOR
Intervention: Computed Tomography (CT)
Number of subjects: 79
Study: 8582152

Group type: EXPERIMENTAL
Intervention: Data archiving for meta-analysis
Number of subjects: 0
Study: 2669571

Group type: EXPERIMENTAL
Intervention: Basilic vein cutdown
Number of subjects: 138

Group type: COMPARATOR
Intervention: Percutaneous subclavian vein placement
Number of subjects: 138
Study: 788910

Group type: EXPERIMENTAL
Intervention: Dihydergot (2.5 mg, 3 times a day for 4 weeks)
Number of subjects: 36

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 36
Study: 31536654

Group type: EXPERIMENTAL
Intervention: Prolonged-release tacrolimus in combination with mycophenolate mofetil (MMF)
Number of subjects: 587

Group type: EXPERIMENTAL
Intervention: Prolonged-release tacrolimus in combination with sirolimus
Number of subjects: 587

Group type: EXPERIMENTAL
Intervention: Prolonged-release tacrolimus-based therapy
Number of subjects: 587
Study: 30958707

Group type: EXPERIMENTAL
Intervention: Isolated hip-focused exercise
Number of subjects: 112

Group type: EXPERIMENTAL
Intervention: Traditional knee-focused exercise
Number of subjects: 112

Group type: COMPARATOR
Intervention: Free physical activity
Number of subjects: 112
Study: 29038901

Group type: EXPERIMENTAL
Intervention: 0.25% bupivacaine with adrenaline
Number of subjects: 100

Group type: COMPARATOR
Intervention: Normal saline (placebo)
Number of subjects: 100
Study: 24700335

Group type: EXPERIMENTAL
Intervention: Bipolar fresh osteochondral allografts (BFOA)
Number of subjects: 7
Study: 24242999

Group type: COMPARATOR
Intervention: Arterolane (RBx11160) maleate 100 mg single oral dose
Number of subjects: 64

Group type: COMPARATOR
Intervention: Arterolane (RBx11160) maleate 25, 50, 100, 150, 200, 300, 400, 600 mg single oral doses
Number of subjects: 64

Group type: COMPARATOR
Intervention: Arterolane (RBx11160) maleate 25, 50, 100, 200 mg multiple oral doses
Number of subjects: 64

Group type: COMPARATOR
Intervention: Arterolane (RBx11160) maleate
Number of subjects: 64

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 64
Study: 22386130

Group type: EXPERIMENTAL
Intervention: Psidium cattleianum leaf extract
Number of subjects: 10

Group type: COMPARATOR
Intervention: Negative control (deionised water)
Number of subjects: 10

Group type: COMPARATOR
Intervention: Active control (commercial mouthwash)
Number of subjects: 10
Study: 19584683

Group type: EXPERIMENTAL
Intervention: Immediate everolimus (IE)
Number of subjects: 139

Group type: COMPARATOR
Intervention: Delayed everolimus (DE)
Number of subjects: 139
Study: 17889468

Group type: EXPERIMENTAL
Intervention: Atuna racemosa extract (MIC=16-32 microg/mL)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 15002002

Group type: EXPERIMENTAL
Intervention: Intervention group (trained in hypertension guidelines)
Number of subjects: 4083

Group type: COMPARATOR
Intervention: Reference group (monitored for efficacy of training)
Number of subjects: 4083

Group type: EXPERIMENTAL
Intervention: Overall population
Number of subjects: 4083
Study: 15857101

Group type: EXPERIMENTAL
Intervention: Autogenous periodontal ligament (PDL) grafts
Number of subjects: 10

Group type: COMPARATOR
Intervention: Coronally advanced flap procedure without graft
Number of subjects: 10
Study: 10589755

Group type: EXPERIMENTAL
Intervention: TLC D‐99 low dose (10 mg/m2)
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: TLC D‐99 high dose (20 mg/m2)
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: TLC D‐99 (combined results)
Number of subjects: 40
Study: 8919705

Group type: EXPERIMENTAL
Intervention: Children of deployed personnel
Number of subjects: 383

Group type: EXPERIMENTAL
Intervention: Families of deployed personnel
Number of subjects: 383

Group type: COMPARATOR
Intervention: Children of nondeployed personnel
Number of subjects: 383
Study: 1928220

Group type: EXPERIMENTAL
Intervention: EDTA infusions (50 mg/kg over three hours)
Number of subjects: 14

Group type: COMPARATOR
Intervention: Placebo infusions
Number of subjects: 14
Study: 6130677

Group type: EXPERIMENTAL
Intervention: Prazosin (2 mg, single oral dose)
Number of subjects: 6
Study: 31914959

Group type: EXPERIMENTAL
Intervention: Pamoja Tunaweza (a locally adapted version of Trauma-focused Cognitive Behavioral Therapy)
Number of subjects: 1200

Group type: EXPERIMENTAL
Intervention: Pamoja Tunaweza
Number of subjects: 1200
Study: 30210115

Group type: EXPERIMENTAL
Intervention: Vonoprazan plus rebamipide (V group)
Number of subjects: 84

Group type: COMPARATOR
Intervention: Esomeprazole plus rebamipide (E group)
Number of subjects: 84
Study: 30672193

Group type: EXPERIMENTAL
Intervention: Blood-letting and cupping therapy combined with basic treatment for 2 weeks, 3 times a week, once every other day.
Number of subjects: 60

Group type: COMPARATOR
Intervention: Basic treatment including internal treatment, acupuncture, and rehabilitation for 2 weeks, 6 times a week, once a day.
Number of subjects: 60
Study: 27113979

Group type: COMPARATOR
Intervention: RT
Number of subjects: 20

Group type: COMPARATOR
Intervention: CRT
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Control
Number of subjects: 20
Study: 25140931

Group type: EXPERIMENTAL
Intervention: BL‐rTMS
Number of subjects: 58

Group type: COMPARATOR
Intervention: HF‐rTMS
Number of subjects: 58
Study: 22406052

Group type: EXPERIMENTAL
Intervention: Group integrated cognitive‐behavioral therapy for 6 months
Number of subjects: 237

Group type: COMPARATOR
Intervention: Twelve‐step facilitation
Number of subjects: 237
Study: 20705946

Group type: EXPERIMENTAL
Intervention: Weight bearing
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: Toe curls
Number of subjects: 10

Group type: COMPARATOR
Intervention: Intermittent pneumatic compression (IPC)
Number of subjects: 10

Group type: COMPARATOR
Intervention: Electrical stimulation
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: Upright position
Number of subjects: 10

Group type: COMPARATOR
Intervention: Supine position
Number of subjects: 10
Study: 18823200

Group type: EXPERIMENTAL
Intervention: Face inversion effect for vertical shifts of the eyes alone
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Focused attention
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Face inversion
Number of subjects: 0
Study: 16022729

Group type: EXPERIMENTAL
Intervention: GORD (G+) group
Number of subjects: 150

Group type: COMPARATOR
Intervention: No GORD (G-) group
Number of subjects: 150

Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 150
Study: 12434950

Group type: EXPERIMENTAL
Intervention: rhTPO and G-CSF
Number of subjects: 68

Group type: COMPARATOR
Intervention: Control (G-CSF only)
Number of subjects: 68
Study: 10357341

Group type: EXPERIMENTAL
Intervention: Mivacurium (MIV)
Number of subjects: 50

Group type: EXPERIMENTAL
Intervention: Succinylcholine (SUCC)
Number of subjects: 50

Group type: COMPARATOR
Intervention: Atracurium (ATR)
Number of subjects: 50

Group type: COMPARATOR
Intervention: Rocuronium (ROC)
Number of subjects: 50

Group type: COMPARATOR
Intervention: Vecuronium (VEC)
Number of subjects: 50
Study: 7792736

Group type: EXPERIMENTAL
Intervention: diet S (C18:0)
Number of subjects: 15

Group type: COMPARATOR
Intervention: diet ML (C12:0 + C14:0)
Number of subjects: 15
Study: 2022441

Group type: EXPERIMENTAL
Intervention: Flurbiprofen 0.03% eye drops
Number of subjects: 0

Group type: COMPARATOR
Intervention: Vehicle application (placebo)
Number of subjects: 0
Study: 31983575

Group type: EXPERIMENTAL
Intervention: VIA-2291 (Atreleuton) 100 mg
Number of subjects: 54

Group type: EXPERIMENTAL
Intervention: VIA-2291 (Atreleuton) (25 mg, 50 mg)
Number of subjects: 54

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 54
Study: 31541251

Group type: EXPERIMENTAL
Intervention: Coated implant (CI; Synovex‐One Feedlot)
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: Implants (both CI and NC)
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: Non-coated implant (NC; Synovex‐PLUS)
Number of subjects: 24

Group type: COMPARATOR
Intervention: No implant (NI)
Number of subjects: 24
Study: 27680592

Group type: EXPERIMENTAL
Intervention: Inulin (8 g/d)
Number of subjects: 36

Group type: COMPARATOR
Intervention: Placebo (maltodextrin, 8 g/d)
Number of subjects: 36
Study: 26383207

Group type: EXPERIMENTAL
Intervention: Sodium thiopental
Number of subjects: 100

Group type: COMPARATOR
Intervention: Propofol
Number of subjects: 100
Study: 23290598

Group type: EXPERIMENTAL
Intervention: Memantine 20 mg orally daily for 26 weeks
Number of subjects: 81

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 81
Study: 21240683

Group type: EXPERIMENTAL
Intervention: Intravenous zoledronic acid (ZOL) 4 mg every 4 weeks
Number of subjects: 55

Group type: COMPARATOR
Intervention: Oral ibandronate (IBA) 50 mg/day
Number of subjects: 55
Study: 19126811

Group type: EXPERIMENTAL
Intervention: Bilateral deep brain stimulation (n = 60) or globus pallidus (n = 61)
Number of subjects: 255

Group type: EXPERIMENTAL
Intervention: Bilateral deep brain stimulation
Number of subjects: 255

Group type: COMPARATOR
Intervention: Best medical therapy (n = 134)
Number of subjects: 255
Study: 16954546

Group type: COMPARATOR
Intervention: Diagnostic doses of 2, 1, and 0.5 mCi (74, 37, and 18.5 MBq)
Number of subjects: 80

Group type: EXPERIMENTAL
Intervention: Therapeutic doses of 150 and 30 mCi (5,550 and 1,110 MBq)
Number of subjects: 80

Group type: EXPERIMENTAL
Intervention: Therapeutic (131)I
Number of subjects: 80
Study: 14764782

Group type: EXPERIMENTAL
Intervention: Supervised exercise for 6 months
Number of subjects: 18
Study: 11562514

Group type: EXPERIMENTAL
Intervention: Single dose sulfited wine challenge (300 ppm)
Number of subjects: 42

Group type: COMPARATOR
Intervention: Double blind, placebo controlled challenge with varying sulfite levels
Number of subjects: 42

Group type: EXPERIMENTAL
Intervention: Cumulative dose sulfited wine challenge
Number of subjects: 42
Study: 9240359

Group type: EXPERIMENTAL
Intervention: Competitive employment
Number of subjects: 143

Group type: COMPARATOR
Intervention: Unemployed patients
Number of subjects: 143
Study: 8119458

Group type: EXPERIMENTAL
Intervention: Cervical laser vaporization treatment
Number of subjects: 46

Group type: COMPARATOR
Intervention: Follow-up without therapy (Control)
Number of subjects: 46
Study: 3630583

Group type: EXPERIMENTAL
Intervention: Ranitidine 2 mg kg‐1
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Ranitidine 2.5 mg kg‐1
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Ranitidine 3 mg kg‐1
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Ranitidine 3.5 mg kg‐1
Number of subjects: 40

Group type: COMPARATOR
Intervention: Control group (no ranitidine)
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: All doses of ranitidine (2-3.5 mg kg‐1)
Number of subjects: 40
Study: 30945490

Group type: EXPERIMENTAL
Intervention: Acu-Moxi group (acupuncture plus herbal-cake partitioned moxibustion)
Number of subjects: 78

Group type: COMPARATOR
Intervention: Control group (routine acupuncture)
Number of subjects: 78

Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 78
Study: 28790270

Group type: EXPERIMENTAL
Intervention: Carotid doppler echo screening
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Carotid artery intervention (carotid endarterectomy or carotid artery stenting)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Off-pump coronary artery bypass grafting
Number of subjects: 0
Study: 26352376

Group type: EXPERIMENTAL
Intervention: Ultrasound guidance
Number of subjects: 47

Group type: COMPARATOR
Intervention: Digital palpation
Number of subjects: 47
Study: 24118425

Group type: EXPERIMENTAL
Intervention: Psoralen-narrowband UVB (P-NBUVB)
Number of subjects: 45

Group type: COMPARATOR
Intervention: Narrowband UVB (NBUVB)
Number of subjects: 45
Study: 21404217

Group type: EXPERIMENTAL
Intervention: MC X11 ASP IOL
Number of subjects: 28

Group type: COMPARATOR
Intervention: AcrySof IQ IOL
Number of subjects: 28
Study: 19303768

Group type: EXPERIMENTAL
Intervention: Long-acting octreotide, 30 mg as an intramuscular injection once every 4 weeks for up to 2 years
Number of subjects: 272

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 272

Group type: EXPERIMENTAL
Intervention: Long-acting octreotide
Number of subjects: 272
Study: 16791019

Group type: EXPERIMENTAL
Intervention: Vitamin A supplementation (400,000 IU within 96 hours post-partum)
Number of subjects: 14110

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 14110

Group type: EXPERIMENTAL
Intervention: Vitamin A supplementation among women with low serum retinol (< 0.7 micromol/l)
Number of subjects: 14110

Group type: EXPERIMENTAL
Intervention: Severe anaemia (haemoglobin < 70 g/l)
Number of subjects: 14110

Group type: EXPERIMENTAL
Intervention: Younger age
Number of subjects: 14110
Study: 14501739

Group type: EXPERIMENTAL
Intervention: Holmium laser enucleation of the prostate (HoLEP)
Number of subjects: 61

Group type: COMPARATOR
Intervention: Transurethral resection of the prostate (TURP)
Number of subjects: 61
Study: 10697447

Group type: EXPERIMENTAL
Intervention: Budesonide, 1200 mcg daily for 6 months followed by 800 mcg daily for 30 months
Number of subjects: 290

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 290
Study: 9377904

Group type: EXPERIMENTAL
Intervention: Growth standards based on birth weight, birth length and birth head circumference
Number of subjects: 0
Study: 8222097

Group type: EXPERIMENTAL
Intervention: Heparin (5000-U intravenous bolus followed by a perfusion titrated to the APTT)
Number of subjects: 484

Group type: COMPARATOR
Intervention: Aspirin (325 mg bid)
Number of subjects: 484

Group type: EXPERIMENTAL
Intervention: Heparin
Number of subjects: 484
Study: 3078624

Group type: EXPERIMENTAL
Intervention: Dexamethasone (0.5 mg/kg preoperatively and 0.25 mg/kg/day for 48 hours postoperatively)
Number of subjects: 36

Group type: COMPARATOR
Intervention: Saline placebo (0.5 mg/kg preoperatively and 0.25 mg/kg/day for 48 hours postoperatively)
Number of subjects: 36
Study: 30334633

Group type: EXPERIMENTAL
Intervention: Secukinumab 150 mg subcutaneously at baseline, Weeks 1, 2, 3, and 4, and every 4 weeks thereafter
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Secukinumab 150 mg
Number of subjects: 30
Study: 30768397

Group type: EXPERIMENTAL
Intervention: Multisystemic therapy
Number of subjects: 684

Group type: COMPARATOR
Intervention: Management as usual
Number of subjects: 684
Study: 28295794

Group type: EXPERIMENTAL
Intervention: Text message intervention
Number of subjects: 67
Study: 25451073

Group type: EXPERIMENTAL
Intervention: Tube drainage
Number of subjects: 40

Group type: COMPARATOR
Intervention: Conventional suturing
Number of subjects: 40
Study: 24366788

Group type: EXPERIMENTAL
Intervention: Ropivacaine (0.5% concentration, 0.5 ml/kg)
Number of subjects: 40

Group type: COMPARATOR
Intervention: Bupivacaine (0.5% concentration, 0.5 ml/kg)
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Ropivacaine
Number of subjects: 40

Group type: COMPARATOR
Intervention: Bupivacaine
Number of subjects: 40
Study: 21970660

Group type: EXPERIMENTAL
Intervention: 5 mg mosapride/10 mg rabeprazole fixed dose combination tablet (T)
Number of subjects: 24

Group type: COMPARATOR
Intervention: Branded formulations of both drugs co-administered in separate tablets (R)
Number of subjects: 24
Study: 19527695

Group type: EXPERIMENTAL
Intervention: Cognitive task (serial subtractions of 3s) during preferred walking pace
Number of subjects: 21

Group type: EXPERIMENTAL
Intervention: Cognitive task (serial subtractions of 3s) during fast walking
Number of subjects: 21

Group type: EXPERIMENTAL
Intervention: Cognitive task (visuo-spatial decision task) during fast walking
Number of subjects: 21

Group type: COMPARATOR
Intervention: Cognitive task (serial subtractions of 3s)
Number of subjects: 21